Pulmatrix Presents Data on iSPERSE for Inhaled Combination Drug Therapies, Including Triple Drug Combinations

LEXINGTON, Mass.--(BUSINESS WIRE)--Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the prevention, treatment and control of respiratory diseases, today announced that its iSPERSE™ inhaled drug platform demonstrated multi-drug delivery capability and superiority over conventional lactose blending for an effective therapeutic dose of the active ingredients in Advair®, salmeterol and fluticasone, as well as an additional anticholinergic bronchodilator. These preclinical data highlight the capability of iSPERSE, a proprietary salt formulation inhaled as a dry powder, to efficiently deliver consistent double- and triple-combination drug doses across a broad range of flow rates, which offers the potential of improved drug efficacy and safety for patients having both normal and lower or impaired lung function. These results were presented in a poster entitled “Pulmonary Delivery of Combination Drug Products via a Novel Dry Powder Delivery Technology” at the 11th US-Japan Symposium on Drug Delivery Systems on December 15-20, 2011, in Lahaina, Hawaii.